← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Queensland University Of Technology
Brisbane
$14,378,624
Total funding
26
Grants
Funding over time
peak $5M · FY2005–24$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
DOD$12,925,866 · 24
NIH$1,452,758 · 2
By mechanism
—$12,925,866 · 24
R01$1,452,758 · 2
Investigators at Queensland University Of Technology
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
THE PURPOSE OF THIS COOPERATIVE AGREEMENT IS TO FUND RESEARCH IN SUPPORT OF BTO IN THE AMOUNT OF 1,025,290 ON CONTRACT HR0011-17-2-0036.$1,901,148
· FY2017 · Defense Advanced Research Projects Agency
NOVEL THERAPEUTIC TARGETING OF NEUROTOXIC GUT MICROBIOTA-DERIVED METABOLITES IN PARKINSON'S DISEASE$1,453,356
· FY2022 · Defense Health Agency
DEVELOPMENT AND TRANSLATION OF A MULTIMODAL THERAPEUTIC AGENT AND MEDICAL COUNTERMEASURE FOR THE TREATMENT OF MILITARY-RELATED TOXIC EXPOSURES$1,214,449
· FY2024 · Defense Health Agency
THERAPEUTIC RESOLUTION OF INFLAMMATION AND NEUROTOXICITY AT THE GUT-BRAIN AXIS FOR DISEASE MODIFICATION IN PARKINSON'S DISEASE$1,186,151
· FY2022 · Defense Health Agency
ACCELERATING THE PRECLINICAL TESTING OF A PROMISING TARGETED THERAPEUTIC FOR TRIPLE-NEGATIVE BREAST CANCER$1,158,742
· FY2020 · Defense Health Agency
TARGETING THE DYSREGULATION OF ADIPONECTIN AS A NOVEL PROSTATE CANCER THERAPY$853,896
· FY2020 · Defense Health Agency
INVESTIGATING THE ROLE OF NOVEL TRANSCRIPTS IN THE MYCN LOCUS DRIVING NEUROENDOCRINE PROSTATE CANCER$824,997
· FY2022 · Defense Health Agency
A NOVEL TARGETED THERAPY FOR TREATMENT-EMERGENT ANAPLASTIC FORMS OF CASTRATION-RESISTANT PROSTATE CANCER$824,927
· FY2022 · Defense Health Agency
THE SHORT AND THE LONG OF A GWAS IDENTIFIED LONG NON-CODING RNA$738,087
· FY2019 · Defense Health Agency
IDENTIFYING AND VALIDATING ONCOGENE-INDUCED MECHANISMS OF IMMUNOSUPPRESSION DOWNSTREAM OF THE ESRP1/FGFR2/KRAS AXIS TO IMPROVE IMMUNOTHERAPY$530,941
· FY2022 · Defense Health Agency
NEW TECHNOLOGY FOR EARLY DETECTION OF RESIDUUM TISSUE DAMAGES.$356,730
· FY2016 · Department of the Army
WEARABLE BIOSENSORS FOR REAL-TIME PHYSIOLOGICAL MONITORING$354,401
· FY2020 · Department of the Army
TARGETING THE PLASTIC NATURE OF PROSTATE CANCER METASTASIS TO IMPROVE THERAPEUTIC STRATEGIES FOR ADVANCED DISEASE.$258,527
· FY2020 · Department of the Army
CHARACTERISATION OF LONG LENGTHS OF COMMERCIAL HIGH TEMPERATURE SUPERCONDUCTING (HTS) TAPE AND WIRE$240,000
· FY2019 · Department of the Navy
Long-Term Ethanol Exposure and Neuronal Nicotinic Acetylcholine Receptors$239,151
R01 · FY2014 · AA
Long-Term Ethanol Exposure and Neuronal Nicotinic Acetylcholine Receptors$229,289
R01 · FY2013 · AA
DESIGNING POLYMERS AS BROAD SPECTRUM ANTIVIRALS TO RAPIDLY FIGHT EMERGING VIRAL INFECTIONS$213,313
· FY2022 · Defense Health Agency
DEVELOPMENT OF HTS TAPE METRICS AND TOOLSETS TO MAXIMISE NAVAL APPLICATION PERFORMANCE AND RESILIENCE$210,500
· FY2023 · Department of the Navy
THE ROLE OF ION CHANNEL GENES IN POST-TRAUMATIC HEADACHE$182,019
· FY2019 · Defense Health Agency
Quantification of the environmental UVA exposure$176,136
R01 · FY2005 · CA